Reliq Health Technologies Has Reached An Inflection Point
The company still saw 36% sequential growth despite Omicron headwind. CAD$2M run rate in December reflects CAD $24M annually; they are still on course to meet CAD$40M 2022 reaffirmed guidance.
The company has an enormous number of signed customers which is increasing on a weekly basis and with the Cognizant partnership, there is a chance to land whales.
Medical platform stocks should do well in this market, although so far they are sharing in the malaise.
Management argues they don’t need additional financing but we’re not entirely convinced here, although it’s entirely possible that option exercise ties them over to cash flow positive.
Looking for more investing ideas like this one? Get them exclusively at SHU Growth Portfolio. Learn More »